Health Canada approves Taltz for pediatric patients with plaque psoriasis – Eli Lilly
Health Canada issued a Notice of Compliance for Taltz (ixekizumab), from Eli Lilly, injection, 80 mg/mL, for the treatment of pediatric patients from six to less than 18… read more.